This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
Hong Jiang
Qingdao University
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Ghrelin has been identified as a multifunctional peptide that has a potential applications for the treatment Parkinson’s disease (PD).
Method: ELISA was used for detecting plasma total and active ghrelin levels, dopamine (DA) content was measured by HPLC-ECD, immunofluorescence staining and Western blot were used to detect protein expressions, and cytokine was tested by Bio-PlexPro™ assay.
Results
Here, we reported a subcutaneous administration of low-dose ghrelin via mini-osmotic pumps to PD mice. The decreased levels of total and active ghrelin in plasma were rescued by ghrelin administration. Interestingly, ghrelin had no effect on weight gain in wild-type mice but improved weight loss in PD mice. We observed the attenuation of dopaminergic (DAergic) neuron loss in substantia nigra (SN) and low level of dopamine content in the striatum in PD mice with ghrelin treatment. Ghrelin administration could improve the environment of DAergic neuron by inhibiting microglia proliferation and pro-inflammatory cytokine expression, and could enhance cell survival by upregulating Bcl-2/Bax ratio and superoxide dismutase1 (SOD1) protein level in SN in PD mice.
Conclusions
Our results suggested that subcutaneous administration of low-dose ghrelin could prevent the onset or the progression of PD, and also provided a possible method for ghrelin application to cure PD.
Keywords
Ghrelin, Parkinson’s disease, Apoptosis, Oxidative stress, Inflammation
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
View the published article at Neurobiology of Aging.
Version 1
Posted 08 Jun, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Neurobiology of Disease
Learn more about our company.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
Hong Jiang
Qingdao University
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
View the published article at Neurobiology of Aging.
Version 1
Posted 08 Jun, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Neurobiology of Disease
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Neurobiology of Aging.
Background
Ghrelin has been identified as a multifunctional peptide that has a potential applications for the treatment Parkinson’s disease (PD).
Method: ELISA was used for detecting plasma total and active ghrelin levels, dopamine (DA) content was measured by HPLC-ECD, immunofluorescence staining and Western blot were used to detect protein expressions, and cytokine was tested by Bio-PlexPro™ assay.
Results
Here, we reported a subcutaneous administration of low-dose ghrelin via mini-osmotic pumps to PD mice. The decreased levels of total and active ghrelin in plasma were rescued by ghrelin administration. Interestingly, ghrelin had no effect on weight gain in wild-type mice but improved weight loss in PD mice. We observed the attenuation of dopaminergic (DAergic) neuron loss in substantia nigra (SN) and low level of dopamine content in the striatum in PD mice with ghrelin treatment. Ghrelin administration could improve the environment of DAergic neuron by inhibiting microglia proliferation and pro-inflammatory cytokine expression, and could enhance cell survival by upregulating Bcl-2/Bax ratio and superoxide dismutase1 (SOD1) protein level in SN in PD mice.
Conclusions
Our results suggested that subcutaneous administration of low-dose ghrelin could prevent the onset or the progression of PD, and also provided a possible method for ghrelin application to cure PD.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Loading...